SCHEMBL2179971

SCHEMBL2179971

CC(C)C(C(=O)O)N1Cc2ccc(-c3ccc(NC(=O)c4ccc(Oc5ccccc5)cc4)cc3)cc2C1=O

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.51
TP53 P04637 1/20 0.51
PGR P06401 2/20 0.46
ABCB1 P08183 1/20 0.45
MCHR1 Q99705 2/20 0.43
SDCBP O00560 2/20 0.43
SDC2 P34741 2/20 0.43
ITGB3 P05106 2/20 0.43
ITGA2B P08514 2/20 0.43
ITGA2 P17301 2/20 0.43
NR1H4 Q96RI1 1/20 0.42
CASP3 P42574 1/20 0.42
SENP8 Q96LD8 1/20 0.42
SENP7 Q9BQF6 1/20 0.42
SENP6 Q9GZR1 1/20 0.42
GHSR Q92847 1/20 0.41
THRB P10828 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2179965 1.00 LMNA (0.51) LMNATP53PGRABCB1MCHR1
SCHEMBL2179677 0.93 LMNA (0.47) LMNATP53PGRMCHR1SDCBP
SCHEMBL2182460 0.93 LMNA (0.52) LMNATP53PGRABCB1MCHR1
SCHEMBL13718946 0.93 LMNA (0.47) LMNATP53PGRMCHR1SDCBP
SCHEMBL2178118 0.93 LMNA (0.48) LMNATP53MCHR1SDCBPSDC2
SCHEMBL13719015 0.93 LMNA (0.48) LMNATP53MCHR1SDCBPSDC2
SCHEMBL2180113 0.93 LMNA (0.48) LMNATP53MCHR1SDCBPSDC2
SCHEMBL2178235 0.92 LMNA (0.53) LMNATP53SDCBPSDC2THRB
SCHEMBL2179239 0.92 LMNA (0.53) LMNATP53SDCBPSDC2THRB
SCHEMBL2179317 0.92 LMNA (0.49) LMNATP53SDCBPSDC2ITGB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US claimed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US claimed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP claimed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO claimed
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US disclosed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US disclosed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP disclosed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE DGAT1, DGAT2, LCAT LMNA 2193/4885TP53 2093/4885PGR 4069/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.